CU24017B1 - Compuestos etanamínicos para tratar la depresión - Google Patents

Compuestos etanamínicos para tratar la depresión

Info

Publication number
CU24017B1
CU24017B1 CU2011000141A CU20110141A CU24017B1 CU 24017 B1 CU24017 B1 CU 24017B1 CU 2011000141 A CU2011000141 A CU 2011000141A CU 20110141 A CU20110141 A CU 20110141A CU 24017 B1 CU24017 B1 CU 24017B1
Authority
CU
Cuba
Prior art keywords
compounds
pharmaceutically acceptable
ethanaminal
acceptable salt
treat depression
Prior art date
Application number
CU2011000141A
Other languages
English (en)
Other versions
CU20110141A7 (es
Inventor
Michael Balestra
Peter Bernstein
Glen E Ernst
William Frietze
John P Mccauley
David Nugiel
Lihong Shen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24017(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CU20110141A7 publication Critical patent/CU20110141A7/es
Publication of CU24017B1 publication Critical patent/CU24017B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)

Abstract

La presente invención trata de compuestos 2-metil-1-fenil-2-(piridin-2-il)propan-1-amina o una sal farmaceuticamente aceptable del mismo y su isómero (S)-2-metil-1-fenil-2-(piridin-2-il)propan-1-amina o una sal farmaceuticamente aceptable del mismo donde la sal farmaceuticamente aceptable es una sal formada a partir de sulfúrico, fosfórico, cítrico, tartárico, láctico, pirúvico, acético, succínico, fumárico, ácido clorhídrico, bromhídrico, maleico, metanosulfónico, o bencenosulfónico. Estos compuestos son útiles para el tratamiento de la depresión.
CU2011000141A 2008-12-24 2011-06-24 Compuestos etanamínicos para tratar la depresión CU24017B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24
PCT/SE2009/051493 WO2010074647A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Publications (2)

Publication Number Publication Date
CU20110141A7 CU20110141A7 (es) 2012-01-31
CU24017B1 true CU24017B1 (es) 2014-07-30

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000141A CU24017B1 (es) 2008-12-24 2011-06-24 Compuestos etanamínicos para tratar la depresión

Country Status (31)

Country Link
US (4) US8013165B2 (es)
EP (2) EP2610246A1 (es)
JP (1) JP5491524B2 (es)
KR (1) KR20110097996A (es)
CN (1) CN102333762B (es)
AR (1) AR074981A1 (es)
AU (1) AU2009330745B2 (es)
BR (1) BRPI0923476A2 (es)
CA (1) CA2748235A1 (es)
CL (1) CL2011001590A1 (es)
CO (1) CO6450688A2 (es)
CR (1) CR20110365A (es)
CU (1) CU24017B1 (es)
DO (1) DOP2011000205A (es)
EA (1) EA201190064A1 (es)
EC (1) ECSP11011161A (es)
GT (1) GT201100186A (es)
HN (1) HN2011001773A (es)
IL (1) IL213518A0 (es)
MX (1) MX2011006680A (es)
NI (1) NI201100131A (es)
NZ (1) NZ593282A (es)
PE (1) PE20120249A1 (es)
SA (1) SA109310013B1 (es)
SG (2) SG192510A1 (es)
SV (1) SV2011003962A (es)
TW (1) TWI442922B (es)
UA (1) UA106056C2 (es)
UY (1) UY32360A (es)
WO (1) WO2010074647A1 (es)
ZA (1) ZA201105441B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5491524B2 (ja) * 2008-12-24 2014-05-14 アストラゼネカ・アクチエボラーグ エタンアミン化合物及びうつ病を処置するためのその使用
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) * 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (es) 1973-05-26 1982-11-30
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) * 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
ATE135206T1 (de) 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) * 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
DK0612314T3 (da) * 1991-10-30 2000-05-29 Astra Ab 2-pyrazinylethylaminderivater og deres anvendelse som lægemidler
ES2115055T3 (es) * 1992-04-03 1998-06-16 Astra Ab 1-fenil-2-(2-piridinil)etilamina enantiomera para el tratamiento de trastornos neurodegenerativos.
ATE227278T1 (de) * 1996-04-19 2002-11-15 Akzo Nobel Nv Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
ATE229004T1 (de) 1997-03-31 2002-12-15 Korea Res Inst Chem Tech Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) * 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
JP5491524B2 (ja) * 2008-12-24 2014-05-14 アストラゼネカ・アクチエボラーグ エタンアミン化合物及びうつ病を処置するためのその使用

Also Published As

Publication number Publication date
CA2748235A1 (en) 2010-07-01
CN102333762B (zh) 2014-06-11
DOP2011000205A (es) 2011-07-15
MX2011006680A (es) 2011-07-12
ZA201105441B (en) 2012-03-28
PE20120249A1 (es) 2012-04-19
NI201100131A (es) 2012-03-19
US20130137731A1 (en) 2013-05-30
JP2012513993A (ja) 2012-06-21
BRPI0923476A2 (pt) 2016-01-19
SV2011003962A (es) 2012-01-06
WO2010074647A1 (en) 2010-07-01
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
TWI442922B (zh) 2014-07-01
AU2009330745B2 (en) 2012-04-05
HN2011001773A (es) 2014-08-18
GT201100186A (es) 2013-10-08
US9035065B2 (en) 2015-05-19
IL213518A0 (en) 2011-07-31
TW201028149A (en) 2010-08-01
EP2391606A1 (en) 2011-12-07
EA201190064A1 (ru) 2012-02-28
UY32360A (es) 2010-07-30
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
EP2610246A1 (en) 2013-07-03
SA109310013B1 (ar) 2013-07-28
EP2391606A4 (en) 2012-06-13
JP5491524B2 (ja) 2014-05-14
AU2009330745A1 (en) 2011-08-04
CU20110141A7 (es) 2012-01-31
CN102333762A (zh) 2012-01-25
CO6450688A2 (es) 2012-05-31
SG171928A1 (en) 2011-07-28
US20120277272A1 (en) 2012-11-01
NZ593282A (en) 2013-06-28
CL2011001590A1 (es) 2012-06-22
ECSP11011161A (es) 2011-07-29
KR20110097996A (ko) 2011-08-31
AR074981A1 (es) 2011-03-02
US8013165B2 (en) 2011-09-06
CR20110365A (es) 2011-08-09

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
CU24000B1 (es) Un derivado 2-carboxamida-cicloamino-urea-tiazol-piridilo
MX346959B (es) Nuevos compuestos triciclicos.
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
MX2012008874A (es) Macrociclos como inhibidores del factor de coagulacion (fxia).
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
MX2012002761A (es) Bipiridinas utiles para el tratamiento de enfermedades proliferativas.
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
CY1123438T1 (el) Διαδικασια για παραγωγη και καθαρισμοανασυνδυασμενης λυσοσωμικης αλφα-μαννοσιδασης
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
CR20110634A (es) Inhibidores de fosfoinositida 3 cinasa y/ u objetivo mamifero de rapamicina
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
WO2011027249A3 (en) Benzimidazole derivatives
ECSP11011157A (es) Inhibidores de proteína cinasa
GEP20156239B (en) Benzofuranyl derivatives used as glucokinase inhibitors
EP2440251A4 (en) INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
IN2012DN01855A (es)
MX344435B (es) Compuestos antitromboticos.
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)